SIRT1 and metabolic dysfunction-associated steatotic liver disease: NAFLD experimental animal model studies show that SIRT1, as a negative regulator of UPR signals, inhibits mechanistic target of rapamycin complex 1 (mTORC1) and endoplasmic reticulum stress, reduces hepatic steatosis, improves insulin resistance, and restores glucose homeostasis [116].